O Keefe Stevens Advisory Inc. Sells 62 Shares of Johnson & Johnson $JNJ

O Keefe Stevens Advisory Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,584 shares of the company’s stock after selling 62 shares during the period. O Keefe Stevens Advisory Inc.’s holdings in Johnson & Johnson were worth $547,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Highline Wealth Partners LLC increased its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson in the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $52,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $188.23 on Tuesday. The company has a 50-day moving average price of $176.62 and a 200-day moving average price of $163.00. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $189.92. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $453.32 billion, a P/E ratio of 20.13, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm posted $2.82 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on JNJ shares. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Bank of America boosted their price target on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research note on Friday. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $189.12.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.